Purpose: To determine whether dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) characteristics of the breast tumor and background parenchyma can distinguish molecular subtypes (ie, luminal A/B or basal) of breast cancer. Materials and Methods: In all, 84 patients from one institution and 126 patients from The Cancer Genome Atlas (TCGA) were used for discovery and external validation, respectively. Thirty-five quantitative image features were extracted from DCE-MRI (1.5 or 3T) including morphology, texture, and volumetric features, which capture both tumor and background parenchymal enhancement (BPE) characteristics. Multiple testing was corrected using the Benjamini-Hochberg method to control the false-discovery rate (FDR). Sparse logistic regression models were built using the discovery cohort to distinguish each of the three studied molecular subtypes versus the rest, and the models were evaluated in the validation cohort. Results: On univariate analysis in discovery and validation cohorts, two features characterizing tumor and two characterizing BPE were statistically significant in separating luminal A versus nonluminal A cancers; two features characterizing tumor were statistically significant for separating luminal B; one feature characterizing tumor and one characterizing BPE reached statistical significance for distinguishing basal (Wilcoxon P < 0.05, FDR < 0.25). In discovery and validation cohorts, multivariate logistic regression models achieved an area under the receiver operator characteristic curve (AUC) of 0.71 and 0.73 for luminal A cancer, 0.67 and 0.69 for luminal B cancer, and 0.66 and 0.79 for basal cancer, respectively. Conclusion: DCE-MRI characteristics of breast cancer and BPE may potentially be used to distinguish among molecular subtypes of breast cancer. Level of Evidence: 3 Technical Efficacy: Stage 3
Luminal tumors represent a majority (70%) of invasive breast cancer. They are generally estrogen-receptor (ER) and/or progesterone-receptor (PR) positive, and respond well to endocrine therapy. 3 Among the four subtypes, luminal A breast cancer has the best prognosis, whereas luminal B cancer tends to be more proliferative, of higher histologic grade, and is associated with a higher risk of early relapse and poorer disease-free survival. 4 On the other hand, basal-like cancer, which is often ER/PR/HER2-negative, is associated with BRCA1 dysfunction and generally has a poor prognosis. 3 Current assessment of molecular subtypes is based on either gene expression profiling (GEP) or immunohistochemistry (IHC). 5 Due to the cost, complexity, and initial requirement of fresh frozen tissue, the use of GEP has been limited in clinical practice. This led to the development of the more practical IHC-based classification of breast cancer, which has high or moderately high concordance with intrinsic molecular subtypes, 1, 5 and subsequently adopted by the St Gallen International Expert Consensus panel 6 to define breast cancer subtypes. Molecular testing requires tissue specimens typically obtained by needle biopsy, and thus can provide inconclusive due to inadequate tumor material or sampling of a small portion of the tumor. Under these circumstances, imaging (in particular, dynamic contrast-enhanced magnetic resonance imaging or DCE-MRI), which shows the entire tumor, may provide information about the molecular subtype. For instance, if initial biopsy indicates luminal A cancer while imaging suggests a high probability of basal-like cancer, repeat biopsy prior to treatment would be warranted given its more aggressive behavior and distinct response to therapy. 7 Previous studies have investigated the relationship between MRI and genomic features [8] [9] [10] [11] [12] [13] or molecular subtypes [14] [15] [16] [17] [18] [19] [20] [21] of breast cancer. However, most studies use a single measurement platform (GEP or IHC) for molecular subtypes and lack independent validation. Additionally, most only focus on the tumor, ignoring the surrounding breast tissue. A few recent studies have shown that the appearance of background parenchymal enhancement (BPE) on DCE-MRI is associated with breast cancer risk, 22, 23 triple-negative breast cancer, 15 response to chemotherapy, 24, 25 local recurrence, 26 disease-free survival, and overall survival, 27 suggesting an important role of BPE in breast cancer. The purpose of this study was to determine whether DCE-MRI characteristics of the breast tumor and background parenchyma could distinguish among molecular subtypes of breast cancer, and to validate the findings on an external independent cohort. We aimed to demonstrate the robustness of our models by evaluating on two distinct measurement platforms (GEP and IHC) to determine molecular subtypes.
Materials and Methods

Patient Population
Under approval from the Institutional Review Board of Hokkaido University Hospital, reports from 84 patients with breast cancer were retrospectively collected at Hokkaido University from February 2012 through May 2013. The inclusion criteria were that patients had 1) pathologically proven invasive carcinomas in the unilateral breast, and 2) no prior hormonal therapy or neoadjuvant chemotherapy. Informed consent was waived according to Ethical Guidelines for Clinical Studies of the Japanese Ministry of Health, Labour, and Welfare. All patient data were anonymized and deidentified prior to analysis. These 84 patients had preoperative bilateral DCE-MRI scan and molecular subtype information available, which comprised the discovery cohort. In addition, we downloaded publicly available breast cancer cases (n 5 139) through The Cancer Imaging Archive (TCIA) for The Cancer Genome Atlas (TCGA). After careful selection (Fig. 1) , 126 patients whose imaging scans acquired from September 1999 through June 2006 were included in this study as an external validation cohort. Patient characteristics are summarized in Table 1 .
Molecular Subtypes
There is high to moderately high agreement between IHC and GEP for endoplasmic reticulum classification of luminal (73-100%) and basal-like 80% breast cancers. 5 For the patients collected from Hokkaido University Hospital, the pathology report of each patient was analyzed. Their tumor specimens via core biopsy were assessed with IHC analysis to determine the status of ER, PR, HER2, and Ki67. Each tumor was classified into four molecular subtypes according to the St Gallen Consensus 2011, 6 with 1)
luminal A, if ER 1 and/or PR1, HER2-, Ki67 < 14%; 2) luminal B, if ER 1 and/or PR1, HER2 overexpressed or Ki67 14%; 3) basal-like, if ER-, PR-, HER2-; and 4) HER2-enriched, if ER-, PR-, and HER21. For patients from TCIA/TCGA, the molecular subtype from the IHC test was not available. Instead, we assessed their intrinsic molecular subtype through analyzing the gene expression profiles of their tumor specimens collected during surgery. The gene expression data, ie, RNA-seqV2 level 3 v. 1.1.0 data, were obtained through the UCSC Cancer Genomics Browser (https://genome-cancer.ucsc.edu, accessed April 1, 2016). PAM50 28 was used to predict the intrinsic molecular subtypes of the breast cancer patients. Specifically, we adopted the 50-gene classifier as defined in PAM50, which consisted of centroids constructed by the PAM algorithm and distances calculated using Spearman's rank correlation. The final subtype classification was assigned based on the nearest five centroids. 28 
Imaging Protocol
For data from Hokkaido University Hospital, MRI was performed with an Achieva 3.0 T TX system (Philips Healthcare, Best, Netherlands) with a 7-channel breast coil in prone position. The dynamic protocol was in accordance with the American College of 3 . An intravenous gadolinium-based contrast agent was delivered with the dose of 0.1 mmol/kg and flushed with 20 mL saline. MR images were acquired at four timepoints, with the first one taken immediately before contrast injection, and the second, third, and fourth timepoints at 1 minute, 2 minutes, and 6 minutes after injection. The quality of the scans was verified for lack of artifacts, patient motion, or poor fat suppression that would negatively impact subsequent image analysis by a radiologist (X.S., 11 years of experience in breast imaging). For the dataset from TCIA/TCGA, DCE-MRI was acquired from six different centers, on a 1.5T or 3T GE, Siemens or Philips whole-body MRI system, with a standard double breast coil. The dynamic protocol used was in accordance with the ACR guidelines. 29 The DCE-MRI protocols include one precontrast image and two to seven postcontrast images (with a gadolinium-based contrast agent), in either the axial or sagittal view. T 1 -weighted images were acquired with a fat-suppressed gradient echo sequence: repetition time ranged from 3.8-8.3 msec, echo time ranged from 1.1-4.2 msec, flip angle ranged from 8-108, in-plane resolution ranged from 0.39-0.97 mm, and the slice thickness ranged from 0.9-3.2 mm.
Tumor and Background Parenchyma Segmentation
Two radiologists (F.K. and X.S., with 14 and 11 years of experience in breast imaging, respectively) blinded to tumor subtypes manually delineated the 3D tumor in a slice-by-slice manner, taking into account all available sequences (such as T 2 -weighted MRI). Both radiologists reached consensus regarding all tumor contours. Then the ipsilateral parenchyma was segmented in an automated fashion from DCE-MRI: first, the breast ROI was segmented, then fuzzy c means clustering separated the entire breast region into fatty tissue and nonfatty tissue (parenchyma and cancer), and lastly the parenchyma tissue was obtained by excluding the predefined tumor region from the nonfatty tissue region. The parenchymal segmentation was manually revised by two radiologists when necessary.
Image Preprocessing
Inconsistency in imaging protocols within TCIA/TCGA and between datasets can cause variability in the quantitative image features. To mitigate this effect and ensure robust feature extraction, we applied several procedures to normalize the imaging data. First, the N4 bias correction 30 was implemented to correct the shading appearing in the MR images. Second, we matched the temporal resolution between the two cohorts. For each patient, we extracted DCE-MRI scans before contrast administration, at an early postcontrast phase (temporal sampling of the center of k-space between 2-3 minutes), and at a late postcontrast phase (around 6 minutes) for further analysis, in accordance with ACR Breast Imaging Reporting and Data System (BI-RADS) and previous multiinstitutional study design. 31 Third, for each patient, the DCE-MRI was normalized via the imaging value of precontrast parenchyma, ie, average of interquartile voxel values from parenchyma before contrast administration, to explicitly account for heterogeneous imaging protocols. Lastly, all the DCE-MR images were resized to have an isotropic voxel resolution of 0.8 mm, which assured meaningful 3D texture feature computation in the following.
Quantitative Image Feature Extraction
We extracted a total of 35 quantitative image features from each patient's DCE-MRI to characterize the tumor and parenchymal enhancement as well as intratumor heterogeneity, as shown in Fig.  2 . The proposed feature pool investigates the phenotypical properties of both tumor and parenchyma, including eight tumor morphological features, 12 tumor texture features, three functional tumor volume features, six parenchymal enhancement features, and six tumor-surrounding parenchymal enhancement features. These features and their potential clinical relevance are elaborated in Table 2 and Supplementary Table 1 . Here we used 4 out of 22 Haralick texture features calculated from the gray-level co-occurrence matrix. These texture features were selected to avoid redundancy and were commonly used in the medical image analysis literature.
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The cutoff values for signal enhancement ratio (SER) and percentage enhancement (PE) were chosen a priori, including low, medium, and high thresholds matched to values at the bottom 10 th percentile, median, and top 10 th percentile. The calculation was implemented with MatLab (MathWorks, Natick, MA).
Model Discovery for Molecular Subtypes
We constructed separate models to distinguish luminal A versus nonluminal A cancers, luminal B versus nonluminal B cancers, as well as basal-like versus nonbasal-like cancers using DCE-MRI features based on the discovery cohort. We did not analyze the HER2-enriched subtype due to a small number of patients in the discovery cohort (n 5 4) and relatively poor agreement (41-69%) between gene expression patterns and IHC surrogates for these subtypes.
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Given the relatively large number of quantitative image features, we combined logistic regression and Least Absolute Shrinkage and Selection Operator (LASSO) 34 to perform feature selection to avoid overfitting. Briefly, 10-fold internal crossvalidation was applied and repeated 100 times to minimize the potential selection bias, and the most frequently selected imaging features were used to fit the final model. For comparison, we assessed the predictive capacity of the clinicopathological information (age, postmenopausal status, and histologic type) as the baseline. The baseline model was fitted with logistic regression in the discovery cohort, using R v. 3.2.3 (Vienna, Austria). In addition, we compared with the predictive capability of the qualitative features by radiologists' reading according to ACR BI-RADS, including mass shape, margin, and internal enhancement characteristics.
Model Validation and Statistical Analysis
We tested the subtype models on the independent external validation cohort. The receiver operating characteristics (ROC) curve analysis and area under the curve (AUC) was used to assess the prediction capability of the proposed imaging predictors. The threshold to separate different molecular subtypes was defined in the discovery cohort based on the Youden's J statistics, 35 and the same threshold was applied to the validation cohort. The corresponding sensitivity, specificity, and accuracy were reported.
Mann-Whitney U statistics tested the statistical significance of the multivariate model (ie, comparing its AUC to a random guess with AUC 5 0.5). The method of DeLong test was utilized in the construction of 95% confidence intervals as well as in computing P-values of the pairwise comparison of ROC curves. To adjust for multiple statistical testing, the Benjamini-Hochberg method was used to control the false-discovery rate (FDR) on univariate analysis. P < 0.05 and FDR less than 0.25 was considered to indicate statistically significant differences. Similar to Ref. 8, a larger threshold of FDR was adopted to increase the likelihood of positive findings. The statistical analysis was in R.
Results
Univariate Analysis
All 35 quantitative imaging features are illustrated in a heatmap in Fig. 3 , and the corresponding Pearson correlation matrix did not indicate that the imaging features were correlated (absolute correlation coefficient <0.8, Supplementary  Fig. 1 ). On univariate analysis, four imaging features were statistically significant in separating luminal A versus nonluminal A patients in the validation cohort (three features had Wilcoxon P < 0.05, FDR < 0.01, one had Wilcoxon P < 0.05, FDR < 0.05). Two quantitative imaging features reached significance to differentiate luminal B from nonluminal B cases in the validation cohort (Wilcoxon P < 0.05, FDR < 0.10). Two quantitative imaging features reached significance to separate basal-like versus nonbasal-like cancers (Wilcoxon P < 0.05, FDR < 0.25). Figure 4 shows the detailed distribution of these six features as well as their FDR adjusted for multiple testing.
Multivariate Analysis
The optimal subtype models respectively for luminal A, luminal B, and basal-like cancer based on the discovery cohort are illustrated in Table 3 . Additionally, the corresponding ROC curves for three molecular subtypes are plotted in Figs. 5 and 6 separately for discovery and validation cohorts. On independent validation, all three models achieved good accuracy and remained statistically significant (Mann-Whitney P < 0.05), as shown in Table 3 . The subtype models based on quantitative imaging features were significantly better than the baseline models consisting of three clinical factors, with Delong P of 0.022, 0.048, and 0.039 for luminal A, luminal B, and basallike breast cancer, respectively.
BI-RADS Features Were Not Predictive Of Molecular Subtypes
The subtype models based on BI-RADS features were inferior to those based quantitative image features, with AUC ranging from 0.56-0.57 (Mann-Whitney P > 0.05) for validation (see Supplementary Fig. 2 ).
Discussion
In this radiogenomic study, we investigated the relationship between DCE-MRI characteristics and intrinsic molecular subtypes of breast cancer. Through extensive image analysis, we extracted quantitative image features of the breast tumor as well as surrounding background parenchyma. Measure the enhanced parenchyma surrounding the tumor within 2cm distance PE: percent enhancement, which is defined as PE5 The ability to accurately define breast cancer molecular subtypes on an individualized basis has important therapeutic implications. For instance, luminal B cancer has a distinct profile of therapeutic response in that it is relatively insensitive to endocrine therapy, and relatively resistant to chemotherapy compared with HER2 and basal subtypes. 36 While patients with the less aggressive luminal A cancer may be adequately treated with endocrine therapy alone, women with luminal B cancer often require more aggressive therapy, possibly by combining endocrine and molecularly targeted therapy. 7 Promising therapeutic targets for luminal B cancers, such as phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitors, are being actively tested and have shown clinical efficacy in prospective trials. 37 Our data suggest that DCE-MRI could be used to identify patients who are more likely to harbor the more aggressive luminal B cancer versus luminal A cancer. Our study builds upon previous radiogenomic work [14] [15] [16] [17] [18] [19] [20] [21] and adds to the accumulating evidence that imaging may potentially provide useful supplementary information to molecular analysis in breast cancer, especially in situations where the latter is inconclusive because of insufficient tumor sampling in a small-needle biopsy.
We showed that luminal A cancer was significantly associated with smaller functional tumor volume, smaller surface area (which is correlated with volume), and smaller volume of enhanced background parenchyma compared to nonluminal A cancer in both cohorts. Previous studies have shown that smaller functional tumor volume and lower BPE around the tumor are associated with superior survival 38 and lower risk of recurrence in breast cancer, 26 respectively.
As luminal A cancer is known to have the best prognosis among all four subtypes, this lends support for our findings here. Conversely, we showed that basal-like breast cancer was significantly associated with larger functional tumor volume and higher tumor surrounding BPE fraction, which also seems to be consistent with a generally poor prognosis of basal-like cancer.
Our data indicate that the more aggressive luminal B cancer was significantly associated with higher intratumor heterogeneity (ie, the lower uniformity of the gray-level cooccurrence matrix) in both cohorts. This adds to the extensive evidence that imaging heterogeneity is associated with aggressive disease in many cancer types. 32 Additionally, a higher volume of BPE conferred a higher risk for luminal B cancer on multivariate analysis in our study, which also appears to be consistent with recent studies showing the associations between higher BPE and a higher risk of local recurrence, 26 as well as worse recurrence-free survival in breast cancer. 39 One recent study specifically looking at the association between DCE-MRI and luminal B breast cancer also showed the relevance of BPE. 17 To quantify the degree of BPE, we used volume-based measurements in our study. This is different from previous studies 26, 27 that calculate the absolute signal enhancement or its ratio of background parenchyma, which may be prone to MR signal artifacts or variations in image acquisition protocols. We believe that volume-based measurements are more robust to such variations 38 and that they are more closely related to how radiologists observe and interpret BPE on MRI, as suggested in BI-RADS. 29 In our study, the molecular subtypes were defined on two different platforms, ie, IHC in the discovery cohort and gene expression profiles in the validation cohort. For luminal and basal cancers, there is a high though not perfect concordance between the two assays (73-100% and 80%), 5 which might explain the variations in different subtype models. Despite the potential difference, we were able to validate our results on two independent platforms, attesting the robustness of the radiogenomic relations found here.
There were a small number (4%) of tumors in the validation cohort that fall into the normal breast-like subtype. Unlike the other four intrinsic molecular subtypes, the normal breast-like subtype is less reproducible, and shows low tumor cellularity (<50%) when examined pathologically, explaining why they group with the true normal samples. 40 Thus, when a tumor is classified as the normal breast-like subtype, it is most likely caused by a false-negative biopsy, where the sample is predominantly composed of normal breast tissue and not tumor tissue. This again points to the potential limitations of molecular analysis based on a needle biopsy, and highlights the value of imaging for depicting the entire tumor volume.
Limitations of our study include the retrospective nature of our external validation cohort. Due to a small sample size, we were not able to study the HER2-enriched subtype. While discovery benefited from the use of a uniform acquisition protocol for MRI, the image data in the validation cohort came from multiple institutions and consisted of several different acquisition protocols and parameters, which might have influenced the image quantification. Nevertheless, we conducted careful image preprocessing and normalization, as well as automated image analysis, to minimize the potential biases (indeed, the results were validated on the external cohort). Our findings need to be further validated in larger prospective cohorts.
In conclusion, DCE-MRI characteristics of the tumor and background parenchyma can be used to distinguish among molecular subtypes of breast cancer. Future studies should be conducted to elucidate the biological mechanism behind these relations.
